News

News

Notice of Website Renewal

News

Notice of Speaking Engagement at the 59th Natural Products Chemistry Discussion Meeting

News

LINK-J Symposium “Drug Discovery Frontier 2026” – Speaking Announcement

News

Notice of Tokyo Office Relocation

Media

Featured in Nikkei Biotech

Media

Featured in The Nikkei

Media

Announcement: Guest Appearance on Radio NIKKEI 1’s The Money – Thursday, Hideaki Sakurai’s Kabutetsu

News

Event Report: CTO Toma Speaks at LINK-J and Merck Co-hosted Symposium

Media

Our CEO Takahara Featured on “IRTV” Video Media

Media

CEO Featured on Radio NIKKEI

News

Selected as a Finalist for the CITELINE Japan Award 2024 Biotech Company of the Year

Media

Notice of Article Published in the Nikkei

News

PRISM BioLab opens a business office in Tokyo

News

Announcement of Initial Listing on Tokyo Stock Exchange Growth Market

News

Notice of Approval for Listing on the Growth Market of the Tokyo Stock Exchange

News

PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono

News

Announcement of setting the record date for stock split

News

PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein-protein interactions

News

PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target

News

PRISM BioLab announces a milestone achievement based on the license agreement with Ohara Pharmaceutical

Media

New study by PRISM Biolab demonstrates rational design of small molecule inhibitors of CTLA-4 and B7-1 protein-protein interaction utilizing only a sequence of a binding peptide

News

Pharma Intelligence Award Japan 2022 Commemorative Webinar “PPI Inhibition by Small Molecules: A New Drug Discovery Paradigm”

News

PRISM Biolab Wins Biotech Company of the Year Award of Informa Pharma Intelligence Award 2022

News

PRISM BioLab, enters multi-project drug discovery collaboration with Roche and Genentech

News

PRISM BioLab raised 100 million yen in Series C funding from Eisai

News

The CREB-binding protein (CBP)/β-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)

News

The paper of peptidomimetics is published in ACS Omega

News

RISM BioLab raised 1.3 billion yen in Series C funding

News

Servier and PRISM BioLab enter drug discovery collaboration for a novel target

News

PRISM Biolab and Merck enter multi-project drug discovery collaboration

News

PRISM Biolab and Boehringer Ingelheim enter multi-project drug discovery collaboration

News

Notice of Our Merger